Psychopathologic and Metabolic Changes in a Patient with Myxedema Psychosis Treated with L-tri-iodothyronine
Abstract
L-tri-iodothyronine was utilized in the treatment of myxedema psychosis. Psychopathology and metabolic state were carefully documented throughout the course of treatment. Part of the psychopathology observed was an organic brain syndrome related to the myxedema. Treatment with L-tri-iodothyronine resulted in disappearance of the organic brain syndrome and return to the euthyroid state. Persisting psychopathology appears related either to a premyxedematous depressive illness or to the response of the patient's personality to the myxedematous state. This segment of the psychopathology was responsive to chlorpromazine and electroconvulsive treatments.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
